You are using an outdated browser. Please upgrade your browser to improve your experience.

trastuzumab emtansine

Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
Target Activities
Items per page:
1 – 10 of 10